We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+50.39%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$3.65B
AUM Growth
+$1.23B
Cap. Flow
+$333M
Cap. Flow %
9.14%
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
82
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$36.8M
2
UNH icon
UnitedHealth
UNH
+$30.1M
3
RPRX icon
Royalty Pharma
RPRX
+$24.7M
4
NVAX icon
Novavax
NVAX
+$21.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$19.5M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$42.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$17.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.7M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.68M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.99%
2 Miscellaneous 1.37%
3 Consumer Staples 1.09%
4 Consumer Discretionary 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
26
DELISTED
Invitae Corporation
NVTA
$45.8M 1.26%
1,511,127
+361,127
+31% +$6.3M
MRSN
27
DELISTED
Mersana Therapeutics
MRSN
$44M 1.21%
75,137
+25,817
+52% +$8.82M
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
$42.5M 1.17%
250,000
+8,000
+3% +$1.19M
PTLA
29
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$41.5M 1.14%
2,306,196
+554,296
+32% +$7.71M
IDXX icon
30
Idexx Laboratories
IDXX
$40.2B
$41.3M 1.13%
125,000
– –
ONC
31
BeOne Medicines Ltd
ONC
$39.2B
$40.5M 1.11%
215,000
+200
+0.1% +$32.6K
EW icon
32
Edwards Lifesciences
EW
$49.4B
$40.2M 1.1%
582,000
– –
FRPT icon
33
Freshpet
FRPT
$3.01B
$39.8M 1.09%
476,000
+78,500
+20% +$5.91M
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$39.8M 1.09%
348,761
+7,261
+2% +$704K
ALGN icon
35
Align Technology
ALGN
$10.4B
$39.2M 1.08%
143,000
+15,500
+12% +$3.49M
BSX icon
36
Boston Scientific
BSX
$63.6B
$38.6M 1.06%
1,100,000
– –
PEN icon
37
Penumbra
PEN
$12.5B
$37M 1.02%
207,000
-18,000
-8% -$3.12M
EXAS
38
DELISTED
Exact Sciences
EXAS
$36.9M 1.01%
424,000
– –
VRTX icon
39
Vertex Pharmaceuticals
VRTX
$130B
$36.3M 1%
125,000
– –
CHRS icon
40
Coherus Oncology
CHRS
$205M
$36.2M 0.99%
2,025,275
+75,275
+4% +$1.27M
APLT
41
DELISTED
Applied Therapeutics
APLT
$35.8M 0.98%
991,573
+145,873
+17% +$6.1M
ASMB icon
42
Assembly Biosciences
ASMB
$532M
$35M 0.96%
124,910
-90
-0.1% -$21K
ARDX icon
43
Ardelyx
ARDX
$878M
$34.7M 0.95%
5,015,109
+165,109
+3% +$1.15M
LKFT
44
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$34.5M 0.95%
175,000
– –
EPZM
45
DELISTED
Epizyme, Inc
EPZM
$33.8M 0.93%
2,104,084
+149,084
+8% +$2.6M
AMRN
46
Amarin Corp
AMRN
$294M
$32.2M 0.88%
232,500
– –
ASND icon
47
Ascendis Pharma A/S
ASND
$15.8B
$31.6M 0.87%
213,500
– –
CI icon
48
Cigna
CI
$76.3B
$30.2M 0.83%
161,000
+20,000
+14% +$3.79M
AMGN icon
49
Amgen
AMGN
$203B
$29.7M 0.82%
126,000
– –
MDGL icon
50
Madrigal Pharmaceuticals
MDGL
$12.1B
$28.8M 0.79%
254,268
+4,268
+2% +$420K
1
2
3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rock Springs Capital Management held 147 positions worth $3.65B, up 51% from $2.42B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $333M of net new capital in Q2 2020, opening 14 new positions and adding to 82 existing holdings. Its largest new stake was Royalty Pharma: 500,000 shares worth $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Intuitive Surgical, an estimated $17.5M trimmed.

  • Rock Springs Capital Management's largest Q2 2020 buy was Royalty Pharma: 500,000 shares worth $24.3M.
  • Rock Springs Capital Management added most to Centene in Q2 2020, an estimated $36.8M increase.
  • Rock Springs Capital Management's biggest Q2 2020 reduction was Intuitive Surgical, cutting an estimated $17.5M.
  • Rock Springs Capital Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $42.7M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $3.65B portfolio in Q2 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 4 in Q2 2020.
  • Rock Springs Capital Management's portfolio value rose 51% quarter-over-quarter to $3.65B.

Based on Rock Springs Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.